Answer
Linagliptin is not recommended for children and adolescents because a clinical trial did not establish efficacy in patients aged 10–17 years, and it has not been studied in children under 10 years.
Sources for this answer
- Trajenta 5 mg film-coated tabletsBoehringer Ingelheim Limited · emc · SmPC §4.2 Posology and method of administration · Version 18Document updated
Sources checked